No effects of ozonated autohemotherapy on inflammation response in hemodialyzed patients
Tylicki L, Biedunkiewicz B, Rachon D, et al. Mediators of Inflammation, 2004.
- Study type
- Controlled trial (non-randomized)
- People studied
- 12 people
- Population
- Chronically hemodialyzed patients with peripheral arterial disease
- Published
- 2004, Mediators of Inflammation
- Identifiers
- PMID 15770057, DOI 10.1080/09629350400014131
What the authors reported
In a controlled, single-blind, cross-over study of 12 hemodialysis patients, nine sessions of ozonated autohemotherapy produced no significant change in plasma C-reactive protein or interleukin-6 compared with nine sham (oxygen-only) autohemotherapy sessions.
What limits this result
Small sample of 12 patients in a single crossover study; a null result for these two inflammatory markers does not rule out other biological effects of ozone.
How ozone acts on blood and cells, how blood filters work, and studies that measure markers in the blood rather than how patients fare. None of these shows whether EBO2 helps patients. One study rarely settles a medical question; our guides weigh each paper against the rest of the evidence.
Where we cite this study
EBO2 (EBOO) vs 10-Pass Ozone and MAH: What Is Actually Different
How EBO2 (EBOO), 10-pass ozone, and major autohemotherapy differ in blood volume, filtration, cost, and what the evidence actually supports.
What Is EBO2 (EBOO) Therapy? Procedure, Evidence, Cost, and Safety
A neutral, sourced explainer of EBO2 (also called EBOO): how the procedure works, what the research shows, typical cost, and the FDA's position.